Business Context and Reporting Period
This Form 8-K was filed by Supernus Pharmaceuticals, Inc. on April 7, 2015, reporting events that occurred on April 2, 2015. The company is a Delaware corporation headquartered in Rockville, Maryland.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial performance.
Material Changes
The primary material event reported is the issuance of a sixth patent by the United States Patent and Trademark Office (USPTO). This patent covers Trokendi XR, the company's novel once-daily extended-release topiramate product.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the patent issuance. The event is presented as a positive milestone for the company's intellectual property portfolio regarding its lead product.
Investor Verification Checklist
- Verify the specific claims and scope of the sixth USPTO patent for Trokendi XR.
- Review the full text of the press release (Exhibit 99.1) for additional details on the patent's impact.
- Confirm the current regulatory status and commercial launch timeline for Trokendi XR.